Abstract
The present application relates to the use of platelet derived growth factor β (PDGFRβ) as a biomarker for fibrosis. More specifically, the invention is directed to in vitro methods of diagnosing fibrosis, diagnosing the severity of fibrosis, determining the prognosis of fibrosis and/or assessing the efficacy of a therapeutic against fibrosis based on the detection and quantification of soluble PDGFRβ (sPDGFRβ) in biological fluid samples. Even more in particular, sPDGFRβ is determined for the diagnosis of liver fibrosis, lung fibrosis or kidney fibrosis. In another further aspect, the detection of sPDGFRβ is combined with the detection and/or quantification of other biomarkers. In a further embodiment detection and quantification of sPDGFRβ is combined with one or more other biomarkers.
Original language | English |
---|---|
Patent number | WO2020099487 |
Publication status | Published - 2020 |